Michael L. Jones - 01 Dec 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: Exec. Director, Finance - PAO
Signature: /s/ Alane P. Barnes, by power of attorney
Issuer symbol: BCRX
Transactions as of: 01 Dec 2022
Net transactions value: -$99,674
Form type: 4
Filing time: 02 Dec 2022, 17:36:04 UTC
Previous filing: 03 Mar 2022
Next filing: 19 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Options Exercise	$12,212	+8,600	+77%	$1.42^*	19,798	01 Dec 2022	Direct
transaction	BCRX	Common Stock	Sale	$111,886	-8,600	-43%	$13.01	11,198	01 Dec 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCRX	Emp. Stock Option (Right to Buy)	Options Exercise	$0	-8,600	-100%	$0.000000^*	0	01 Dec 2022	Common Stock	8,600	$1.42	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.01 to $13.03. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.